Etta has partnered with the largest medical institution in the United States,Mayo Clinic,and established a joint venture,Mettaforge Therapeutics,on July 3, 2019,in the U.S.Mayo Clinic invested in the venture and provided gene editing technology and clinical medical resources,while Etta supplied electroporation equipment and technology for the development of non-viral vector universal cell immunotherapy drugs,and is seeking to raise funds and list in the U.S.Etta is the second-largest shareholder of the joint venture.Dr. Dai also serves as the CEO of the company.The founding team of Mettaforge includes several prominent figures in addition to Dr. Dai as an electroporation expert and one of the operational leaders(Figure 1):Dr. Steven Ekker,a Mayo Clinic professor,is the Dean of the Mayo Graduate School,a gene editing expert,and holds multiple gene editing technology patents,including CellSmith and transposons;Dr.Saad Kenderian,a Mayo Clinic professor,is the chief CAR-T clinician at Mayo and comes from the team of Dr.Carl June,the father of CAR-T.The joint venture’s advisors include Dr.Franklyn Prendergast,former director at Mayo and board member of Eli Lilly,who founded the Mayo Clinic Cancer Center and the Center of Individualized Medicine,and Dr. Carl June.